NCT05691504 Testing the Combination of APG-1252 (Pelcitoclax) and Cobimetinib in Recurrent Ovarian and Endometrial Cancers Status ACTIVE_NOT_RECRUITING Phase PHASE1
NCT05441514 Enasidenib in Combination With Cobimetinib for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia Status COMPLETED Phase PHASE1
NCT04409639 Cobimetinib in Newly Diagnosed or HMA-treated CMML Patients With RAS Pathway Mutations Status ACTIVE_NOT_RECRUITING Phase PHASE2
NCT04302025 A Study of Multiple Therapies in Biomarker-selected Participants With Resectable Stages IB-III Non-small Cell Lung Cancer (NSCLC) Status RECRUITING Phase PHASE2
NCT04216953 MEK Inhibitor and a PDL1 Inhibitor Patients With Locally Advanced and/or Metastatic Soft Tissue Sarcoma Status COMPLETED Phase PHASE1/PHASE2
NCT03768063 A Study in Patients Previously Enrolled in a Genentech and/or F. Hoffmann-La Roche Ltd Sponsored Atezolizumab Study Status ACTIVE_NOT_RECRUITING Phase PHASE3
NCT03554083 Vemurafenib, Cobimetinib, Atezolizumab, and Tiragolumab in Treating Patients With High-Risk Stage III Melanoma Status COMPLETED Phase PHASE2
NCT03337698 A Study Of Multiple Immunotherapy-Based Treatment Combinations In Participants With Metastatic Non-Small Cell Lung Cancer (Morpheus- Non-Small Cell Lung Cancer) Status TERMINATED Phase PHASE1/PHASE2
NCT03202940 A Phase IB/II Study of Alectinib Combined With Cobimetinib in Advanced ALK-Rearranged (ALK+) NSCLC Status ACTIVE_NOT_RECRUITING Phase PHASE1/PHASE2